Results of a 4-year follow-up of patients on the Herceptin Adjuvant (HERA) trial have been published in March edition of Lancet Oncology.
Axillary lymph node dissections (ALND) remain the standard of care for breast cancer patients that have sentinel lymph node metastases. However, the procedure carries the risk of serious complications such as infection, lymphedema, and seroma.
Esophageal cancer generally has a poor prognosis; while preoperative chemotherapy is recommended, tumors often do not respond to treatment.
After the initial excitement over the potential of RNAi to target any cancer gene, the field is now being viewed with caution and a bit of skepticism. Delivery system issues need to be solved and substantial clinical data of patient responses from early-stage trials need to be shown for the field to look promising.
A meta-analysis study of 3784 clinical trial patients from five clinical trials taking bevacizumab for breast cancer published in the Journal of Clinical Oncology has found that although the incidence for significant heart failure is low, patients have an increased risk of developing significant heart failure.
For the first time, a series of metastatic melanoma (MM) patients have been genetically tested for the constitutively activating BRAF mutation and assessed for its prognostic significance as is routinely done for breast cancer (HER2) and chronic myeloid leukemia (ABL).
The use of oral bisphosphonates, typically used to treat osteoporosis and bone metastases in breast cancer, has recently been found to reduce breast cancer risk.
Researchers at the Queen Mary U. of London and a team of collaborators have identified a genetic signature among prostate tumors that may facilitate determining appropriate course of treatment for patients. The results of the study will be published in the March 2011 issue of Lancet Oncology.
A new study finds that cancer cells, conventionally thought to develop only over long periods of time can begin in a single event, accounting for the development of 2% to 3% of all cancers, and up to 25% of bone cancers.
Researchers at Baylor and affiliated institutions reported in the January issue of the New England Journal of Medicine that the addition of iniparib to chemotherapy improves the clinical benefit and survival of patients with metastatic triple-negative breast cancer, without significantly increased toxic effects.